Secukinumab: A Biologic To Treat Psoriasis
Il-17 targeting is the new trend in the biologic systemic treatment of psoriasis. Ustekinumab (Stelara) is the main one used today in that sense. Secukinumab: is a fully anti-interleukin-17A monoclonal antibody is (at the time of publishing this article) the latest Il-17A drug to have exited phase III trials. The results out of two studies…